CURRICULUM VITAE
Sameem Abedin MD
Sameem Abedin MD
Associate Professor
Department of Medicine
Division of Hematology and Oncology - Medicine
Department of Medicine
Division of Hematology and Oncology - Medicine
OFFICE ADDRESS: |
Froedtert Hospital |
9200 W Wisconsin Ave |
Milwaukee, WI 53226 |
Phone: 414-805-4600 |
Email: sabedin@mcw.edu |
EDUCATION: |
09/2000 - 05/2004 BA, University of Pennsylvania, Philadelphia, PA |
07/2005 - 06/2009 MD, Sidney Kimmel Medical College, Thomas Jefferson Univ, Philadelphia, PA |
POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS: |
07/2009 - 06/2012 Resident, Clinical Research Training Program, Internal Medicine, University of Pittsburgh, Pittsburgh, PA |
07/2014 - 06/2017 Fellowship in Hematology/Oncology, Medicine, Hematology/Oncology, Northwestern University, Chicago, IL |
07/13/2016 - 07/18/2016 Scholar, American Society of Bone Marrow Transplant (ASBMT), Clinical Research Training Course, ASBMT, Park City, UT |
07/2016 - 06/2017 Chief Fellow, Medicine, Hematology/Oncology, Northwestern University, Chicago, IL |
08/01/2017 - 06/30/2019 Scholars Progam, Medicine, Hematology/Oncology, Clinical and Translational Science Institute, Milwaukee, WI |
FACULTY APPOINTMENTS: |
07/2012 - 06/2014 Clinical Lecturer, Internal Medicine, General Medicine, University of Michigan, Ann Arbor, MI |
07/2017 - Present Assistant Professor, Medicine, Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI |
HOSPITAL AND CLINICAL ADMINISTRATIVE APPOINTMENTS: |
03/2021 - Present Medical Director, Inpatient Translational Research Unit (TRU), Inaugural medical director. Oversaw the planning and launch of the inpatient TRU This unit addresses the rapid growth of early phase clinical trials requiring coordinated inpatient care., Froedtert Hospital, 9200 W. Wisconsin Avenue, Milwaukee, WI |
03/2021 - Present Director, Adult Early Phase Program in Hematologic Malignancies, Cancer Center, Inaugural director, Oversee the portfolio of hematologic malignancy focused adult Phase I studies, from start-up to enrollment. Presently, this portfolio consists of over 30 trials., Medical College of Wisconsin, 9200 W. Wisconsin Avenue, Milwaukee, WI |
02/2023 - Present Assistant Director, Clinical Trials Office (CTO), Medicine, Oversee cancer clinical trial activation at MCW Oversee hematologic malignancy clinical trial program., Medical College of Wisconsin, 9200 W. Wisconsin Avenue, Milwaukee, WI |
HOSPITAL STAFF PRIVILEGES: |
07/01/2012 - 06/30/2014 Attending Physician, Medicine, Hospital Medicine, University of Michigan, Ann Arbor, MI |
07/15/2017 - Present Attending Physician, Medicine, Hematology and Oncology, Medical College of Wisconsin/Froedtert, Milwaukee, WI |
SPECIALTY BOARDS AND CERTIFICATION: |
Board Certified | Issue Date | Expiration |
Internal Medicine | 2012 | 2022 |
Medical Oncology | 2017 | 2027 |
Licensure | Number | Issue Date | Expiration |
PA Medical License | 2009 | 2012 | |
MI Medical License | 2012 | 2014 | |
IL Medical License | 2014 | 2017 | |
WI Medical License | 2017 | 2025 | |
AWARDS AND HONORS: |
2008 - 2009 Hobart Amory Hare Medical Honor Society, Sidney Kimmel Medical College |
2009 Foerderer Award for International Study, Sidney Kimmel Medical College |
2016 ASBMT Clinical Research Scholar, ASBMT |
2017 - 2019 CTSI Clinical Research Scholar, CTSI of Southeast Wisconsin |
2018 - 2019 Faculty Development Award, Medical College of Wisconsin |
2019 Moderator, American Society of Hematology Annual Meeting, Acute Myeloid Leukemia: Clinical Studies |
2019 Top Patient Experience Award, Froedtert Hospital |
2020 Scientific Discussant, American Society of Clinical Oncology Annual Meeting, Novel Treatments in Acute Leukemia |
2020 - Present Moderator, American Society of Hematology Annual Meeting, Acute Myeloid Leukemia: Clinical Studies |
MEMBERSHIPS IN HONORARY AND PROFESSIONAL SOCIETIES: |
07/2014 - Present American Society of Hematology |
07/2016 - Present American Society of Transplantation and Cellular Therapy |
EDITORSHIPS/EDITORIAL BOARDS/JOURNAL REVIEWS: |
Journal Review |
07/2016 - Present Reviewer, Leukemia and Lymphoma |
07/2019 - Present Blood Advances |
07/2019 - Present PLOS One |
07/2019 - Present Biology of Blood and Marrow Transplantation |
Ad-Hoc Reviewer |
07/2019 - Present Invited abstract reviewer, American Society of Hematology annual meeting |
07/2020 - Present Invited abstract reviewer, American Society of Hematology annual meeting |
NATIONAL ELECTED/APPOINTED LEADERSHIP AND COMMITTEE POSITIONS: |
10/2018 Member, Oncology Standard Setting Committee, American Board of Internal Medicine |
07/2019 - 06/2021 Member, Biomarker Committee, Bone Marrow Transplant-Clinical Trials Network |
10/2020 - Present Member, Older Adult Leukemia Working Group, Southwest Oncology Group (SWOG) |
07/2021 - Present Member, Friday Satellite Symposia Study Section, American Society of Hematology |
08/2021 - Present Member, Leukemia Core Committee, Eastern Cooperative Oncology Group (ECOG) |
07/11/2023 - Present Planning member, Appointed to Chair, CME-certified educational program, Preceding American Society of Hematology annual meeting |
RESEARCH GRANTS/AWARDS/CONTRACTS/PROJECTS: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
INVITED LECTURES/WORKSHOPS/PRESENTATIONS: |
National |
Sameem Abedin, Acute Myeloid Leukemia: Clinical Studies, American Society of Hematology Annual Meeting, Orlando, FL, 12/2019 |
Sameem Abedin, Novel Treatments in Acute Leukemia, American Society of Clinical Oncology Annual Meeting, Chicago, IL (virtual), 05/2020 |
Sameem Abedin, Acute Myeloid Leukemia: Clinical Studies, American Society of Hematology Annual Meeting, San Diego, CA (virtual), 12/2020 |
Regional |
Sameem Abedin, ML in 2019: Approaching the Vision of Precision Medicine, 8th Annual Controversies in Heme Malignancies Symposium, Milwaukee, WI, 02/2019 |
Sameem Abedin, Novel Therapies for Relapsed AML, 2nd Annual Midwest Cellular Therapies Symposium, Chicago, IL, 04/2022 |
Local |
Sameem Abedin, Aspirin and its Role in Colorectal Cancer Prevention, University of Pittsburgh Medicine Grand Rounds, Pittsburgh, PA, 2012 |
Sameem Abedin, Cyclin Dependent Kinase 9 Inhibition as a Therapeutic Target in AML, Robert H Lurie Comprehensive Cancer Center Grand Rounds, Chicago, IL, 2016 |
Sameem Abedin, Acute Myeloid Leukemia: Updates in Management, Froedtert Hospital CFAC education series, Milwaukee, WI, 08/2017 |
Sameem Abedin, Best of ASH in 2017: AML, Division of Hematology/Oncology, Department of Medicine, Milwaukee, WI, 01/24/2018 |
Sameem Abedin, ASH Updates in ALL (excluding CAR-T), Division of Hematology/Oncology, Department of Medicine, Milwaukee, WI, 01/22/2019 |
Sameem Abedin, Updates in CLL, OncLive State of the Science Summit, Milwaukee, WI, 04/2019 |
Sameem Abedin, What's New in Acute Myeloid Leukemia, Department of Medicine Grand Rounds, Medical College of Wisconsin, Milwaukee WI, 11/01/2019 |
Sameem Abedin, Navigating the Therapeutic Landscape of CLL, OncLive State of the Science Summit, Milwaukee, WI, 05/2021 |
PEER REVIEWED WORKSHOPS/PRESENTATIONS: |
National |
Sameem Abedin, A Phase I Study of Lintuzumab-Ac225 in Combination with CLAG-M Chemotherapy in Relapsed/Refractory AML, Oral Presentation, ASH Annual Meeting, San Diego, CA (virtual), 12/05/2020 |
Sameem Abedin, Lintuzumab-Ac225 in Combination with Intensive Chemotherapy Yields High Response Rate and MRD Negativity in R/R AML with Adverse Features, Oral Presentation, ASH Annual Meeting, New Orleans, LA, 12/10/2022 |
COMMITTEE SERVICE: |
Medical College of Wisconsin |
03/2018 - Present Inaugural Member (This committee meets weekly and was created to enable efficient reviews of amendments, mainly for cancer related clinical trials.), Institutional Review Board, Committee #6, Hematology and Oncology, Medicine, Medical College of Wisconsin |
EXTRAMURAL TEACHING: |
Medical Student Education |
08/2017 - Present Adult Inpatient Leukemia Service preceptor, Froedtert Hospital, I attend on the adult inpatient leukemia service 6 weeks per year. During these weeks, I precept one fellow, two residents, and one medical student, and additionally perform bedside teaching, and didactic sessions. |
07/2019 - 05/2020 Clinical and Translational Research Pathway small group facilitator |
08/2019 - Present Adult Outpatient Leukemia/BMT Clinic preceptor, Froedtert Cancer Center, I precept one fellow on the Bone Marrow Transplant Elective weekly. I precept one fellow on the outpatient Leukemia Elective weekly. I precept one resident monthly. I precept medical students on outpatient electives approximately 6 times per year. |
11/2022 - Present MCWFusion Phase 1 Heme-Imm Course instructor, Medical College of Wisconsin, I teach the Reactive and Neoplastic Myeloid Processes Application Exercises session. |
Resident and Fellow Education |
01/2018 - Present Hematology/Oncology Fellowship Core Curriculum Lectures, Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, •Myelodysplastic Syndromes, 1/2018
•Acute Myeloid Leukemia, 2/2018
•Bone Marrow Transplant for AML, 5/2018
•Myelodysplastic Syndromes, 11/2018
•Allogeneic Bone Marrow Transplant, 11/2020 |
Continuing Medical Education |
03/2019 - 03/2022 Co-organizing Director, Controversies in Hematologic Malignancies Symposium, Annual educational symposium related to hematologic malignancies for Wisconsin NPIPAs, pharmacists, and community oncologists hosted by MCW and Aurora. Nearly 150 practitioners attend annually. Co-director for 1O'h, 1 Jlh, and 12th annual symposium. |
Community/Lay Public |
02/2018 Froedtert Hospital Community Education Event, Milwaukee, WI, Sameem Abedin, Acute Myeloid Leukemia |
09/2018 Leukemia and Lymphoma Society Blood Cancer Conference 2018, Milwaukee, WI, Sameem Abedin, Transplants 101: Autologous and Allogeneic, |
10/2020 Lymphoma Research Foundation, (national webinar), Sameem Abedin, Understanding Stem Cell Transplantation and GVHD |
10/2021 Leukemia and Lymphoma Society Blood Cancer Conference 2021, (national webinar), Sameem Abedin, Chronic Myeloid Leukemia |
MCW STUDENTS, FACULTY, RESIDENTS AND CLINICAL/RESEARCH FELLOWS MENTORED: |
Residents |
09/2017 - 08/2018 Edward J McKenna, MD, Internal Medicine Resident, Research Advisor, Medical College of Wisconsin, Manuscript, Original Publication #20 |
09/2017 - 08/2018 Ensi Voshtina, DO, Internal Medicine Resident, Research Advisor, Medical College of Wisconsin, Presentation at a national meeting, Abstract #5 |
09/2018 - 06/2019 Kristin Corrao, DO, Internal Medicine Resident, Research Advisor, Medical College of Wisconsin, Abstract publication at a national meeting, Abstract#11 |
Faculty |
09/2017 - 06/2018 GS Guru Murthy, MD, Fellow, Research Advisor, Medical College of Wisconsin, Poster presentation at a national meeting, Abstract #9, #20 |
09/2017 - 06/2019 Talha Badar, MD, Fellow, Research Advisor, Medical College of Wisconsin, Abstract publication at a national meeting, Abstract #12, Original Publication #41 |
EXTRAMURAL STUDENTS, FACULTY, RESIDENTS, AND CLINICAL/RESEARCH FELLOWS MENTORED: |
Undergraduate Students |
01/2020 - Present Siam Rezuan, undergraduate student, Research Advisor, Johns Hopkins University, Manuscript, Original Publication #40 |
PROGRAMMATIC DEVELOPMENTS: |
Clinical Programs |
01/2018 - Present Graft-vs-Host Disease Adjudication Committee
*Co-direct a third-party GVHD review committee to score acute GVHD
and chronic GVHD events for the purpose of clinical trial endpoint reportin
|
01/2018 - Present GSPMC Molecular Review Hematologic Malignancy
*Co-direct a committee enabling systematic review of all clinical genomic studies for the purpose of clinical trial screening. |
BIBLIOGRAPHY |
Refereed Journal Publications/Original Papers |
1. Abedin S, Michel JJ, Lemster B, Vallejo AN. Diversity of NKR expression in aging T cells and in T cells of the aged: the new frontier into the exploration of protective immunity in the elderly. Exp Gerontol. 2005 Jul;40(7):537-48. |
2. Shaikh N, Abedin S, Docimo SG. Can ultrasonography or uroflowmetry predict which children with voiding dysfunction will have recurrent urinary tract infections? J Urol. 2005 Oct;174(4 Pt 2):1620-2; discussion 1622. |
3. Seo HS, Abedin S, Kamp D, Wilson DN, Nierhaus KH, Cooperman BS. EF-G-dependent GTPase on the ribosome. conformational change and fusidic acid inhibition. Biochemistry. 2006 Feb 28;45(8):2504-14. |
4. Dvergsten JA, Mueller RG, Griffin P, Abedin S, Pishko A, Michel JJ, Rosenkranz ME, Reed AM, Kietz DA, Vallejo AN. Premature cell senescence and T cell receptor-independent activation of CD8+ T cells in juvenile idiopathic arthritis. Arthritis Rheum. 2013 Aug;65(8):2201-10. PMCID: PMC3729743 |
5. Abedin S, Peres E, Levine JE, Choi S, Yanik G, Couriel DR. Double umbilical cord blood transplantation after novel myeloablative conditioning using a regimen of fludarabine, busulfan, and total lymphoid irradiation. Biol Blood Marrow Transplant. 2014 Dec;20(12):2062-6. PMCID: PMC4291068 |
6. Abedin S, Yanik GA, Braun T, Pawarode A, Magenau J, Goldstein SC, Levine JE, Kitko CL, Couriel DR. Predictive value of bronchiolitis obliterans syndrome stage 0p in chronic graft-versus-host disease of the lung. Biol Blood Marrow Transplant. 2015 Jun;21(6):1127-31. PMCID: PMC4970454 |
7. Abedin S, Platanias LC. Whole-exome sequencing for relapse prediction in patients discontinuing TKI treatment in chronic myeloid leukemia. Leuk Lymphoma. 2016 Jul;57(7):1503-4. |
8. Kosciuczuk EM, Saleiro D, Kroczynska B, Beauchamp EM, Eckerdt F, Blyth GT, Abedin SM, Giles FJ, Altman JK, Platanias LC. Merestinib blocks Mnk kinase activity in acute myeloid leukemia progenitors and exhibits antileukemic effects in vitro and in vivo. Blood. 2016 Jul 21;128(3):410-4. PMCID: PMC4957163 |
9. Abedin SM, Boddy CS, Munshi HG. BET inhibitors in the treatment of hematologic malignancies: current insights and future prospects. Onco Targets Ther. 2016;9:5943-5953. PMCID: PMC5047722 |
10. Abedin S, Altman JK. Acute promyelocytic leukemia: preventing early complications and late toxicities. Hematology Am Soc Hematol Educ Program. 2016 Dec 02;2016(1):10-15. PMCID: PMC6142484 |
11. Abedin S, Platanias LC. PD1 and PDL1 upregulation and survival after decitabine treatment in lower risk MDS. Leuk Lymphoma. 2017 Apr;58(4):764-765. |
12. Bell JB, Abedin S, Platanias LC. Circulating microRNAs: promising biomarkers in aplastic anemia. Haematologica. 2017 Jan;102(1):1-2. PMCID: PMC5210225 |
13. Abedin S, Platanias LC. Implications of high EVI1 expression in high-risk myelodysplastic syndromes. Leuk Lymphoma. 2018 Dec;59(12):2765-2766. |
14. Raj RV, Abedin SM, Atallah E. Incorporating newer agents in the treatment of acute myeloid leukemia. Leuk Res. 2018 Nov;74:113-120. |
15. Guru Murthy GS, Pondaiah SK, Abedin S, Atallah E. Incidence and survival of T-cell acute lymphoblastic leukemia in the United States. Leuk Lymphoma. 2019 May;60(5):1171-1178. |
16. Guru Murthy GS, Hari PN, Szabo A, Pasquini M, Narra R, Khan M, Abedin S, Chhabra S, Dhakal B, D'Souza A, Drobyski WR, Rizzo JD, Runaas L, Shah NN, Shaw B, Saber W, Fenske T, Hamadani M. Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Performed in the Inpatient versus Outpatient Setting. Biol Blood Marrow Transplant. 2019 Apr;25(4):827-833. |
17. Beauchamp EM, Abedin SM, Radecki SG, Fischietti M, Arslan AD, Blyth GT, Yang A, Lantz C, Nelson A, Goo YA, Akpan I, Eklund EA, Frankfurt O, Fish EN, Thomas PM, Altman JK, Platanias LC. Identification and targeting of novel CDK9 complexes in acute myeloid leukemia. Blood. 2019 Mar 14;133(11):1171-1185. PMCID: PMC6418475 |
18. Patel AB, Pettijohn EM, Abedin SM, Raps E, Deininger MW. Leukemoid reaction in chronic myelomonocytic leukemia patients undergoing surgery: perioperative management recommendations. Blood Adv. 2019 Apr 09;3(7):952-955. PMCID: PMC6457233 |
19. Guru Murthy GS, Abedin S. Myeloid malignancies after treatment for solid tumours. Best Pract Res Clin Haematol. 2019 Mar;32(1):40-46. |
20. Abedin S, McKenna E, Chhabra S, Pasquini M, Shah NN, Jerkins J, Baim A, Runaas L, Longo W, Drobyski W, Hari PN, Hamadani M. Efficacy, Toxicity, and Infectious Complications in Ruxolitinib-Treated Patients with Corticosteroid-Refractory Graft-versus-Host Disease after Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2019 Aug;25(8):1689-1694. |
21. Abedin SM, Platanias LC. Natural killer cell activity and survival after azacitidine treatment in high-risk MDS. Leuk Lymphoma. 2019 Oct;60(10):2343-2344. |
22. Kosciuczuk EM, Kar AK, Blyth GT, Fischietti M, Abedin S, Mina AA, Siliezar R, Rzymski T, Brzozka K, Eklund EA, Beauchamp EM, Eckerdt F, Saleiro D, Platanias LC. Inhibitory effects of SEL201 in acute myeloid leukemia. Oncotarget. 2019 Dec 24;10(67):7112-7121. PMCID: PMC6935253 |
23. Kosciuczuk EM, Kar AK, Blyth GT, Fischietti M, Abedin S, Mina AA, Siliezar R, Rzymski T, Brzozka K, Eklund EA, Beauchamp EM, Eckerdt F, Saleiro D, Platanias LC. Inhibitory effects of SEL201 in acute myeloid leukemia Oncotarget. 2019;10(67):7112-7121. |
24. Guru Murthy GS, Szabo A, Michaelis L, Carlson KS, Runaas L, Abedin S, Atallah E. Improving Outcomes of Acute Promyelocytic Leukemia in the Current Era: Analysis of the SEER Database. J Natl Compr Canc Netw. 2020 Feb;18(2):169-175. |
25. Abedin SM, Hamadani M. Ruxolitinib: a potential treatment for corticosteroid refractory acute graft-versus-host disease. Expert Opin Investig Drugs. 2020 May;29(5):423-427. |
26. George G, Rezazadeh A, Zook F, Pearl N, McCoy C, Carlson K, Runaas L, Abedin S, Guru Murthy GS, Michaelis LC, Atallah E, Baumann-Kreuziger L. Reducing venous thrombosis with antithrombin supplementation in patients undergoing treatment for ALL with Peg-asparaginase—A real world study Leukemia Research. July 2020;94. |
27. Abid MB, Hamadani M, Szabo A, Hari PN, Graham MB, Frank MO, Collier WS, Abedin S, Jerkins JH, Pasquini MC, Runaas L, Shah NN, Chhabra S. Severity of Cytokine Release Syndrome and Its Association with Infections after T Cell-Replete Haploidentical Related Donor Transplantation. Biol Blood Marrow Transplant. 2020 Sep;26(9):1670-1678. |
28. George G, Rezazadeh A, Zook F, Pearl N, McCoy C, Carlson K, Runaas L, Abedin S, Guru Murthy GS, Michaelis LC, Atallah E, Baumann-Kreuziger L. Reducing venous thrombosis with antithrombin supplementation in patients undergoing treatment for ALL with Peg-asparaginase-A real world study. Leuk Res. 2020 Jul;94:106368. |
29. Chhabra S, Abedin S, Graham MB, Ferrer Marrero TM, Hari PN, Shaw BE. Letter to the Editor Regarding "Diagnostic Considerations for COVID-19 in Recipients of Allogeneic Hematopoietic Cell Transplantation". Biol Blood Marrow Transplant. 2020 Sep;26(9):e241-e242. PMCID: PMC7309826 |
30. Chhabra S, Visotcky A, Pasquini MC, Zhu F, Tang X, Zhang MJ, Thompson R, Abedin S, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Douglas Rizzo J, Runaas L, Saber W, Shah NN, Shaw BE, Horowitz MM, Hari PN, Hamadani M. Ixazomib for Chronic Graft-versus-Host Disease Prophylaxis following Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2020 Oct;26(10):1876-1885. PMCID: PMC7571859 |
31. Mushtaq MU, Harrington AM, Chaudhary SG, Michaelis LC, Carlson KB, Abedin S, Runass L, Callander NS, Fallon MJ, Juckett M, Hall AC, Hematti P, Mattison RJ, Atallah EL, Guru Murthy GS. Comparison of salvage chemotherapy regimens and prognostic significance of minimal residual disease in relapsed/refractory acute myeloid leukemia. Leuk Lymphoma. 2021 Jan;62(1):158-166. |
32. Abid MB, Chhabra S, Buchan B, Graham MB, Abedin S, Thapa B, D'Souza A, George B, Hamadani M. Bronchoalveolar lavage-based COVID-19 testing in patients with cancer. Hematol Oncol Stem Cell Ther. 2021 Mar;14(1):65-70. PMCID: PMC7543702 |
33. Abedin S, Hamadani M. Experimental Pharmaceuticals for Steroid-Refractory Acute Graft-versus-Host Disease. J Exp Pharmacol. 2020;12:549-557. PMCID: PMC7705269 |
34. Chhabra S, Visotcky A, Pasquini MC, Zhu F, Tang X, Zhang MJ, Thompson R, Abedin S, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Rizzo JD, Runaas L, Saber W, Shah NN, Shaw BE, Horowitz MM, Hari PN, Hamadani M. Corrigendum to ‘Ixazomib for chronic Graft-Versus-Host Disease prophylaxis following allogeneic hematopoietic cell transplantation’ [Biology of Blood and Marrow Transplantation 26/10 (2020) 1876-1885] (Biology of Blood and Marrow Transplantation (2020) 26/10(1876-1885) (S1083879120304146), (10.1016/j.bbmt.2020.07.005)) Transplantation and Cellular Therapy. 2021. |
35. Abedin S, Rashid N, Schroeder M, Romee R, Nauffal M, Alhaj Moustafa M, Kharfan-Dabaja MA, Palmer J, Hogan W, Hefazi M, Larson S, Holtan S, DeFilipp Z, Jayani R, Dholaria B, Pidala J, Khimani F, Grunwald MR, Butler C, Hamadani M. Ruxolitinib resistance or intolerance in steroid-refractory acute graft-versus-host disease - a real-world outcomes analysis. Br J Haematol. 2021 Nov;195(3):429-432. PMCID: PMC9293486 |
36. Dhakal B, Abedin S, Fenske T, Chhabra S, Ledeboer N, Hari P, Hamadani M. Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy. Blood. 2021 Oct 07;138(14):1278-1281. PMCID: PMC8332674 |
37. Kunte S, Rybicki L, Viswabandya A, Tamari R, Bashey A, Keyzner A, Iqbal M, Grunwald MR, Dholaria B, Elmariah H, Ozga M, Singh A, Abedin S, DeZern AE, Jones RJ, Gupta V, Gerds AT, Jain T. Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study. Leukemia. 2022 Mar;36(3):856-864. PMCID: PMC10084790 |
38. Abid MB, Rubin M, Ledeboer N, Szabo A, Longo W, Mohan M, Shah NN, Fenske TS, Abedin S, Runaas L, D'Souza A, Chhabra S, Dhakal B, Hamadani M. Efficacy of a third SARS-CoV-2 mRNA vaccine dose among hematopoietic cell transplantation, CAR T cell, and BiTE recipients. Cancer Cell. 2022 Apr 11;40(4):340-342. PMCID: PMC8864440 |
39. Mohan M, Nagavally S, Shah N NN, Michaelis L, Chhabra S, Souza AD, Abedin S, Runaas L, Guru Murthy GS, Longo W, Hamadani M, Dhakal B, Hari P, Fenske TS. Shorter Interval between Treatment and COVID Immunization Is Associated With Poor Seroconversion in Patients with Hematological Malignancies. Clin Lymphoma Myeloma Leuk. 2022 Jul;22(7):e495-e497. PMCID: PMC8767926 |
40. Corrao K, Rezwan S, Atallah E, Michaelis LC, Runaas L, Harrington AM, Abedin S. Prognostic impact of immunophenotypic aberrancies of blasts in lower risk myelodysplastic syndrome. Leuk Res Rep. 2022;17:100329. PMCID: PMC9150024 |
41. Abedin SM, Badar T, Gauger K, Michaelis LC, Runaas L, Carlson KS, Murthy GG, Atallah E. Safety and efficacy of pracinostat in combination with gemtuzumab ozogamicin (PraGO) in patients with relapsed/refractory acute myeloid leukemia. Leuk Res. 2022 Dec;123:106984. |
42. Chhabra S, Visotcky A, Pasquini MC, Zhu F, Tang X, Zhang MJ, Thompson R, Abedin S, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Rizzo JD, Runaas L, Saber W, Shah NN, Shaw BE, Horowitz MM, Hari PN, Hamadani M. Corrigendum to 'Ixazomib for chronic Graft-Versus-Host Disease prophylaxis following allogeneic hematopoietic cell transplantation' [Biology of Blood and Marrow Transplantation 26/10 (2020) 1876-1885]. Transplant Cell Ther. 2022 Oct;28(10):717. |
43. Jain T, Tsai HL, Elmariah H, Vachhani P, Karantanos T, Wall S, Gondek L, Bashey A, Keyzner A, Tamari R, Grunwald M, Abedin S, Nadiminti K, Iqbal M, Gerds A, Viswabandya A, McCurdy S, Malki MA, Varadhan R, Ali H, Gupta V, Jones RJ, Otoukesh S. Haploidentical Donor Blood or Marrow Transplantation for Myelodysplastic/Myeloproliferative Overlap Neoplasms: Results from a North American Collaboration. Res Sq. 2023 Mar 21. PMCID: PMC10055643 |
44. Chhabra S, Jerkins JH, Monahan K, Szabo A, Shah NN, Abedin S, Runaas L, Fenske TS, Pasquini MC, Shaw BE, Drobyski WR, Saber W, D'Souza A, Dhakal B, Mohan M, Longo W, Hamadani M. Severity and organ distribution of chronic graft-versus-host disease with posttransplant cyclophosphamide-based versus methotrexate/calcineurin inhibitor-based allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2024 Mar;59(3):373-379. |
45. Abid MB, Rubin M, Szabo A, Longo W, Fenske TS, McCoy C, Lorge A, Abedin S, D'Souza A, Dhakal B, Shah NN, Hamadani M. Efficacy of Multiple SARS-CoV-2 Vaccine Doses in Patients with B Cell Hematologic Malignancies Receiving Chimeric Antigen Receptor T Cell Therapy: A Contemporary Cohort Analysis. Transplant Cell Ther. 2024 Mar;30(3):285-297. |
46. Jain T, Tsai HL, Elmariah H, Vachhani P, Karantanos T, Wall SA, Gondek LP, Bashey A, Keyzner A, Tamari R, Grunwald MR, Abedin S, Nadiminti KV, Iqbal M, Gerds AT, Viswabandya A, McCurdy SR, Al Malki MM, Varadhan R, Ali H, Gupta V, Jones RJ, Otoukesh S. Haploidentical donor hematopoietic cell transplantation for myelodysplastic/myeloproliferative overlap neoplasms: results from a North American collaboration. Haematologica. 2023 Dec 01;108(12):3321-3332. PMCID: PMC10690921 |
47. Murthy GSG, Saliba AN, Szabo A, Harrington A, Abedin S, Carlson K, Michaelis L, Runaas L, Baim A, Hinman A, Maldonado-Schmidt S, Venkatachalam A, Flatten KS, Peterson KL, Schneider PA, Litzow M, Kaufmann SH, Atallah E. A phase I study of pevonedistat, azacitidine, and venetoclax in patients with relapsed/refractory acute myeloid leukemia. Haematologica. 2024 Sep 01;109(9):2864-2872. PMCID: PMC11367232 |
48. Kim NH, Hamadani M, Abedin S. New investigational drugs for steroid-refractory acute graft-versus-host disease: a review of the literature. Expert Opin Investig Drugs. 2024 Aug;33(8):791-799. PMCID: PMC11305901 |
49. Furqan F, Bhatlapenumarthi V, Dhakal B, Fenske TS, Farrukh F, Longo W, Akhtar O, D'Souza A, Pasquini M, Guru Murthy GS, Runaas L, Abedin S, Mohan M, Shah NN, Hamadani M. Outpatient administration of CAR T-cell therapies using a strategy of no remote monitoring and early CRS intervention. Blood Adv. 2024 Aug 27;8(16):4320-4329. PMCID: PMC11372811 |
50. Abedin S, Hamadani M. Contemporary Updates in the Prevention and Treatment of Graft-Versus-Host Disease. Curr Hematol Malig Rep. 2024 Dec;19(6):246-255. |
51. Watts J, Minden MD, Bachiashvili K, Brunner AM, Abedin S, Crossman T, Zajac M, Moroz V, Egger JL, Tarkar A, Kremer BE, Barbash O, Borthakur G. Phase I/II study of the clinical activity and safety of GSK3326595 in patients with myeloid neoplasms. Ther Adv Hematol. 2024;15:20406207241275376. PMCID: PMC11406655 |
Books, Chapters, and Reviews |
1. Abedin S, Atallah E. Chapter 48. Langerhans Cell Histiocytosis, Erdheim-Chester Disease, Rosai-Dorfman Disease, & Histiocytic Sarcoma. Handbook of Hematologic Malignancies, second edition |
Abstracts |
1. Rios, J, Abedin, S, Rosenzweig, P, Brufsky, A. Methallothionein expression and outcome in patients with metastatic breast cancer (MBC). Poster presented at: ASCO Annual Meeting 2012; Chicago, IL |
2. Abedin, S, Yanik, G, Magenau, J, Pawarode, A, Goldstein, S, Kitko, C, White, E, Couriel, D. The Use of Early Spirometric Changes and IGF-1 Levels for the Early Detection of Patients at Risk for BOS. Poster presented at: BMT Tandem Meetings 2013; Salt Lake City, UT |
3. Abedin, S, Kruse, ML et al. HER2 copy number on FISH as a predictor of disease severity in HER2-negative Breast Cancer. Poster presented at: SABC 2013; San Antonio, TX |
4. Vostina, E, Singavi, AK, Jacquart A, Runaas L, Atallah, EL, Michaelis LC, Abedin, S. Systematic Screening for Familial Leukemia Based on Somatic Genomic Profiling Results. Presented at: ASH Annual Meeting 2018; San Diego, CA |
5. Mushtaq MU, Chaudhary SG, Michaelis LC, Carlson K, Abedin S, Runass L, Fallon MJ, Harrington AM, Juckett M, Hall AC, Mattison RJ, Atallah EL, and Guru Murthy GS. Comparison of Salvage Chemotherapy Regimens in Relapsed/Refractory Acute Myeloid Leukemia. Poster presented at: ASH Annual Meeting 2018; San Diego, CA |
6. Corrao KM, Michaelis LC, Baumann Kreuziger L, Carlson K, Abedin S, Malosh E, Atkinson D, Shan W, Quinet S, Umpierrez De Reguero A, Julie D, Treml A, Runaas L, and Atallah EL. 40 Is the New 50: Reducing the Need for Platelet Transfusions Prior to Lumbar Puncture in Patients with Hematologic Malignancies. Poster presented at: ASH Annual Meeting 2018; San Diego, CA |
7. Abedin S, Guru Murthy GS, Runaas L, et al. Lintuzumab Ac-225 in Combination with CLAG-M in Relapsed/Refractory AML: Interim Results of a Phase I Study. Poster presented at: ASH Annual Meeting 2019; Orlando, FL |
8. Watts J, Bradley T, Thomassen A, Brunner A, Minden M, Papadantonakis N, Abedin S, et al. A Phase I/II Study to Investigate the Safety and Clinical Activity of the Protein Arginine Methyltransferase 5 inhibitor GSK3326595 in Subjects with Myelodysplastic Syndrome and Acute Myeloid Leukemia. Poster Presented at: ASH Annual Meeting 2019; Orlando, FL |
9. Corrao K, Harrington AM, Kroft SH, Michaelis LC, Carlson KS, Runaas L, Atallah E, Abedin S. The Prognostic Significance of Blast Aberrancies By Flow Cytometry in Low/Int Risk MDS. Blood. 2019 Oct; 134: Supplement 1: 5430 |
10. Abedin S, Hamadani M, Holtan SG, et al. Neihulizumab (ABGN-168H) In Patients with Steroid-Refractory Acute Graft-Versus-Host-Disease (SR-AGVHD): Preliminary Results of a Phase I Study: Poster presented at: EHA 2020 |
11. Rezazadeh A, George G, Pearl N, McCoy C, Zook F, Jung B, Aschbrenner E, Waggoner M, Abedin S. et al. Reducing Venous Thrombosis with Antithrombin Supplementation in Patients Undergoing Treatment for ALL with Asparginase Based Regimens. Poster presented at: ASH Annual Meeting 2018; San Diego, CA |
12. Badar T, Guru Murthy GS, Runaas L, Carlson KB, Michaelis LC, Harrington AM, Atallah EL, Abedin S. Phase I Study of Pracinostat in Combination with Gemtuzumab Ozogamicin (PraGO) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML). Abstract Presented at: ASH Annual Meeting 2019; Orlando, FL
|
13. Pollyea D, Stahl M, Talati C, Asghari H, Lai C, Abedin S. et al. Characteristics and Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients Receiving Venetoclax Combinations Vs Other Therapies: Results from the AML Real World Evidence (ARC) Initiative: Poster presented at: ASH Annual Meeting 2020; virtual |
14. Kunte S, Rybicki L, Viswabandya A, Bashey A, Iqbal M, Grunwald MR, Dholaria B, Elmariah H, Ozga M, Singh AK, Abedin S, et al. Haploidentical Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide in Patients with Myelofibrosis: A Multi-Institutional Experience: Poster presented at: ASH Annual Meeting 2020; virtual |
15. Guru Murthy GS, Kauffmann, SH, Szabo A, Harrington AM, Michaelis LC, Abedin S, et al. A Phase I Study of Pevonedistat, Azacitidine and Venetoclax for Patients with Relapsed/Refractory Acute Myelogenous Leukemia (AML): Poster presented at: ASH Annual Meeting 2021; Atlanta, GA |
16. Altman JK, Bhatnagar B, Abedin S, Prezpolewski A, et al. Gilteritinib Can be Safely Combined with Atezolizumab for the Treatment of Relapsed or Refractory FLT3-Mutated AML Results of a Phase I Study: Poster presented at: ASH Annual Meeting 2021; Atlanta, GA |
17. Garcia JS, Wolach 0, Vachhani P, Zeidner J, Abedin Set al. Comparative Effectiveness of Venetoclax Combinations Vs Other Therapies Among Patients with Newly Diagnosed Acute Myeloid Leukemia: Results from the AML Real World Evidence (ARC) Initiative: Poster presented at: ASH Annual Meeting 2021; Atlanta, GA |
18. Konopleva M, Brander OM, Patel K, Abedin Set al. A Phase 1 Dose-Escalation Study of the Oral CDK Inhibitor Voruciclib in Patients with Relapsed/Refractory B-Cell Malignancies or Acute Myeloid Leukemia (AML): Preliminary Results of the Completed Dose Escalation Stage in AML: poster presented at: ASH Annual Meeting 2021; Atlanta, GA |
19. Abedin S, Guru Murthy GS, Hamadani M, Michaelis LC, Runaas L, Carlson K, Atallah EL. Lintuzumab-Ac225 in Combination with CLAG-M Yields High MRD (-) Responses in R/R AML with Adverse Features: Interim Results of a Phase I Study: Poster presented at: ASH Annual Meeting 2021; Atlanta, GA |
20. Vachhani P, Wolach 0, Garcia JS, Abedin Set al. Real-World Management of Patients with
Newly Diagnosed Acute Myeloid Leukemia Treated with Venetoclax-Based Regimens: Results from the AML Real World Evidence (ARC) Initiative: Poster presented at: ASH Annual Meeting 2021; Atlanta, GA
|
21. Guru Murthy GS, Kearl TJ, Cui W, Johnson B, Hoffmeister K, Szabo A, Aoki K, Harrington AM, Carlson K, Michaelis LC, Runaas S, Abedin S, et al. A Phase I Study of XmAb18968, a CD3-CD38 Bispecific Antibody for the Treatment of Patients with Relapsed/Refractory Acute Leukemia and T Cell Lymphoblastic Lymphoma: Poster Presented at: ASH Annual Meeting 2021; Atlanta, GA |
22. Guru Murthy GS, Kaufmann S, Saliba A, Szabo A, Michaelis L, Abedin S, et al. Pevonedistat, azacytidine, and venetoclax for patients with relapsed/refractory Acute Myeloid Leukemia-A Phase I Study. Poster presented at EHA Congress 2022; Vienna, Austria |
23. Wolach J, Garcia JS, Vachhani P, Zeidner J, Lai C, Moshe Y, Xavier M, Lee S, Zuckerman T, Pollyea DA, Abedin S, et al. Transfusion Independence among newly diagnosed Acute Myeloid Leukemia Patients Receiving Venetoclax-based combinations vs other therapies: Results from the AML Real World Evidence (ARC) Initiative. Poster presented at EHA Congress 2022; Vienna, Austria
|
24. Hanrahan JR, Seymour LJ, Beckius A, Welter D, Kastner M, Ehrlich V, Broge-Reynen K, Rodgers M, Michaelis LC, Runaas L, Atallah EL, Abedin S, et al. Standardized Communication Tool Improves Inpatient-Outpatient Care Transitions for Adult with Acute Leukemia. Poster Presented at: ASH Annual Meeting 2022; New Orleans, LA |
25. Jain T, Tsai HL, Elmariah H, Vachhani P, Karantanos T, Wall SA, Gondek LP, Bashey A, Keyzner A, Grunwald MR, Abedin S, et al. Haploidentical Donor Transplantation with Posttransplantation Cyclophosphamide in Myelodysplastic/Myeloproliferative Neoplasms: A Multi-Institutional Collaboration of 14 Centers. Poster Presented at: ASH Annual Meeting 2022; New Orleans, LA |
26. Abedin S, Hamadani M, Holtan S, et al. Neihulizumab (ALTB-168) in patients with Steroid Refractory Acute Graft-Versus-Host-Disease (SR-aGVHD) or Treatment-Refractory Acute Graft-Versus-Host-Disease (TR-aGVHD). Poster Presented at: ASH Annual Meeting 2022; New Orleans, LA |
27. Wolaj 0, Garcia JS, Desai P,Vachhani P, Zeidner J, Abedin Set al. Comparison of Patients with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Treated with Venetoclax and Hypomethylating Agents Vs Other Therapies By TP53 and IDHl/2 Mutation: Results from the AML Real World Evidence (ARC) Initiative. Poster Presented at: ASH Annual Meeting 2022; New Orleans, LA |
28. Abedin S, Taylor S, Guru Murthy GS, et al. Outcomes of Patients Treated with Low Intensity Re-Induction Therapy for Persistent Disease after a Single Intensive Induction Cycle for Newly Diagnosed Acute Myeloid Leukemia (AML). Poster Presented at: ASH Annual Meeting 2022; New Orleans, LA |
29. Gyurkocza B, Seropian S, Choe H, Litzow MR, Abboud C, Koshy N, Stiff PJ, Tomlinson B, Abhyankar SH, Foran J, Hari P, Chen GL, Al-Kadhimi Z, Kebriaei P, SabloffM, Orozco JJ, Jamieson K, Magalhaes-Silverman M, van Besien K, Schuster MW, Law A, Abedin S, et al. Efficacy and Safety Results of the Sierra Trial: A Multicenter, Pivoal Phase 3 Study of lomab-B Prior to Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care in Older Patients with Active, Relapsed or Refractory Acute Myeloid Leukemia (R/R AML). Late Breaking Abtract at: 2023 Tandem Meetings; Orlando, FL |
30. Abedin S, Yanik G, Magenau JM, et al. Application of BOS 0-Potential Criteria As a Predictor for Bronchiolitis Obliterans Syndrome in Allogeneic Stem Cell Transplant Patients. Poster presented at: ASH Annual Meeting 2013; New Orleans, LA |
